https://phys.org/ en-us Latest news from European League Against Rheumatism Diabetes mellitus and gout are ranked among the most common metabolic disorders in Western industrialized countries: According to figures published by the World Health Organization (WHO), around 60 million Europeans suffer from diabetes and 18 million Europeans suffer from gout. "Gout is increasingly being linked to unfavorable cardiovascular, renal and metabolic complications, and now amputation risks," says EULAR president Professor Iain B. McInnes from Glasgow, Scotland, Great Britain. In a current study, Brian Lamoreaux, MD, MS from Lake Forest/USA showed how high the risk of amputations of outer limbs is by evaluating 190 million data sets from a patient database. https://medicalxpress.com/news/2020-08-amputations-body-combination-diabetes-gout.html Diabetes Thu, 13 Aug 2020 13:37:24 EDT news516544640 A large European cross-sectional study has now examined which factors delay the diagnosis of axSpA. A major factor is the number and type of medical professionals who have assessed the patients. https://medicalxpress.com/news/2020-08-axial-spondyloarthritis.html Arthritis & Rheumatism Tue, 11 Aug 2020 10:33:55 EDT news516360831 Disease-related, profound fatigue impairs the quality of life of many people with rheumatic and musculoskeletal diseases. A Belgian study has now concluded that early intensive treatment combining methotrexate with a bridging scheme of prednisone can reduce the onerous fatigue—this also applies to patients at low risk of a severe course. The European League against Rheumatism (EULAR) therefore recommends, that even in so-called low-risk patients, early consideration should be given to whether intensive treatment should be initiated. https://medicalxpress.com/news/2020-06-early-intensive-treatment-rheumatoid-arthritis.html Arthritis & Rheumatism Wed, 17 Jun 2020 12:31:10 EDT news511615867 Fentanyl, tramadol or tilidine: New European figures show that even in Europe increasingly more people are taking opioids for pain connected with rheumatic and musculoskeletal diseases. Current analysis from Catalonia, Spain convincingly shows that the consumption of opioids in patients with osteoarthritis (OA/arthrosis) in 2007 to 2016 increased from 15 to 25 percent in all patients recorded. The survey is based on the health data (SIDIAP, System for the Development of Research in Primary Care) of 80 percent of the population of the Spanish autonomous region which is roughly six million patients. The European League Against Rheumatism (EULAR) is indicating in the course of its annual European E-Congress of Rheumatology 2020 the growing risk of opioid abuse in Europe and calls for measures to use these analgesics more safely. EULAR 2020 takes place from 3 June 2020 as an online congress due to the Covid-19 pandemic. https://medicalxpress.com/news/2020-06-increasingly-patients-opioids-rheumatic-pain.html Arthritis & Rheumatism Thu, 04 Jun 2020 10:46:12 EDT news510486369 Different groups of drugs are used for the treatment of rheumatic conditions. They are intended to suppress the rogue immune system which attacks its own body. It is unclear to date whether the use of immunosuppressants increases the risk of a severe course in case of an infection with the novel coronavirus SARS-CoV-2. A current study published in the run-up to the European Congress of Rheumatology of the EULAR (European League Against Rheumatism) analyzed, for the first time, 600 COVID-19 cases in rheumatic disease patients from 40 countries and investigated the impact of the choice of rheumatic disease therapy on potential hospitalization and the course of COVID-19. The results of the study will be presented in an online press conference in the context of the EULAR Congress on 3 June 2020. https://medicalxpress.com/news/2020-06-covid-rmd-reassurance-patients-immunosuppressive.html Diseases, Conditions, Syndromes Wed, 03 Jun 2020 12:30:02 EDT news510406047 Patients repeatedly express their concern that anti-rheumatic drugs could promote the development of breast cancer. In an autoimmune inflammatory disease such as rheumatoid arthritis (RA), the immune system attacks the body's own structures. This can be prevented by taking immunosuppressive drugs, which inhibit parts of the body's own immune defense. The potential disadvantage: weakening the body's immune system might make it less prone to fight emergent cancers. Earlier studies therefore reported an increased risk of some cancer types in rheumatic diseases. https://medicalxpress.com/news/2020-05-rheumatoid-arthritis-anti-hormonal-breast-cancer.html Arthritis & Rheumatism Wed, 13 May 2020 12:57:25 EDT news508593440 The European League Against Rheumatism (EULAR) launches a European paediatric and adult database to monitor and report outcomes of COVID-19 occurring in patients with rheumatic and musculoskeletal diseases with the support of the Global Rheumatology Alliance. https://medicalxpress.com/news/2020-03-eular-covid-rmd-database-global.html Diseases, Conditions, Syndromes Tue, 31 Mar 2020 13:43:54 EDT news504881030 The campaign presented today at the Annual European Congress of Rheumatology (EULAR 2019) reports how the Cyprus League Against Rheumatism (CYPLAR) successfully took on the Ministry of Health after authorisation was denied to introduce specialised rheumatology nurses due to a perceived lack of interest in rheumatology education. https://medicalxpress.com/news/2019-06-patient-vital-people-rheumatic-diseases.html Arthritis & Rheumatism Fri, 14 Jun 2019 02:49:51 EDT news479699385 The results of a survey presented today at the Annual European Congress of Rheumatology (EULAR 2019) highlight the significant impact of rheumatic and musculoskeletal diseases (RMDs) on mental health and a worrying lack of psychological care. https://medicalxpress.com/news/2019-06-suicidal-thoughts-pain-patients-rheumatic.html Arthritis & Rheumatism Fri, 14 Jun 2019 02:48:52 EDT news479699325 The results of a phase 2B study presented today at the Annual European Congress of Rheumatology (EULAR 2019) demonstrate superior efficacy and comparable safety of tildrakizumab versus placebo in patients with psoriatic arthritis. https://medicalxpress.com/news/2019-06-tildrakizumab-efficacy-safety-psoriatic-arthritis.html Arthritis & Rheumatism Fri, 14 Jun 2019 02:47:59 EDT news479699270 The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2019) demonstrate increased rates of type I diabetes and inflammatory bowel disease (IBD) in patients that go on to develop rheumatoid arthritis (RA). https://medicalxpress.com/news/2019-06-inflammatory-bowel-disease-diabetes-chances.html Arthritis & Rheumatism Fri, 14 Jun 2019 02:47:22 EDT news479699233 The results of a large pan-European survey presented today at the Annual European Congress of Rheumatology (EULAR 2019) investigated significant gaps in rheumatoid arthritis care across 16 patient-centred Standards of Care (SoC) in rheumatoid arthritis. https://medicalxpress.com/news/2019-06-reveals-significant-gaps-essential-rheumatoid.html Arthritis & Rheumatism Fri, 14 Jun 2019 02:45:40 EDT news479699089 The results of a pilot study presented today at the Annual European Congress of Rheumatology (EULAR 2019) suggest that electro stimulation of one of the nerves connecting the brain to the body (the vagus nerve), could provide a novel treatment approach for patients with rheumatoid arthritis. https://medicalxpress.com/news/2019-06-vagus-nerve-significant-reduction-rheumatoid.html Arthritis & Rheumatism Fri, 14 Jun 2019 02:44:05 EDT news479699036 The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2019) identify ApoB:A1 ratio and metabolomic lipoprotein signatures as potential biomarkers for cardiovascular risk in patients with juvenile-onset systemic lupus erythematosus (JSLE). https://medicalxpress.com/news/2019-06-biomarkers-cardiovascular-patients-juvenile-onset-lupus.html Arthritis & Rheumatism Thu, 13 Jun 2019 03:24:46 EDT news479615075 The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2019), jointly organised with the Paediatric Rheumatology Society (PReS), demonstrate no vaccine infections, and no disease flare, in the 234 rheumatic patients who received live-attenuated booster vaccination while taking immune suppressing therapies. https://medicalxpress.com/news/2019-06-debunks-theoretical-live-attenuated-vaccines-children.html Arthritis & Rheumatism Thu, 13 Jun 2019 03:23:59 EDT news479615028 The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2019) demonstrate reduced risk of venous thromboembolism and persistent pain, but increased risk of revision in partial versus total knee replacement in patients with osteoarthritis. https://medicalxpress.com/news/2019-06-patients-venous-thromboembolism-persistent-pain.html Arthritis & Rheumatism Thu, 13 Jun 2019 03:21:43 EDT news479614891 The results of a phase IIa clinical trial presented today at the Annual European Congress of Rheumatology (EULAR 2019) demonstrate a rapid reduction in albuminuria and hyperuricaemia in patients with type II diabetes with combined treatment of verinurad and febuxostat. https://medicalxpress.com/news/2019-06-verinurad-febuxostat-significantly-albuminuria-hyperuricaemia.html Arthritis & Rheumatism Thu, 13 Jun 2019 03:20:54 EDT news479614848 The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2019) suggest that overall cancer risk is not linked to tumour necrosis factor inhibitor (TNFi) use in psoriatic arthritis. https://medicalxpress.com/news/2019-06-link-cancer-tumor-necrosis-factor.html Arthritis & Rheumatism Thu, 13 Jun 2019 03:19:48 EDT news479614780 The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2019) finds the risk of bone mineral density (BMD) loss after denosumab discontinuation is associated with younger age, high bone turnover markers, and not receiving the bisphosphonate, zoledronate, prior to initiation of denosumab. https://medicalxpress.com/news/2019-06-bisphosphonate-prior-denosumab-loss-bone.html Arthritis & Rheumatism Thu, 13 Jun 2019 03:19:09 EDT news479614738 The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2019) suggest maintenance therapy with cyclosporine (CYA) results in more rapid remission of proteinuria compared to mycophenolate mofetil (MMF) or azathioprine (AZA) in patients with lupus nephritis. The efficacy of CYA, MMF and AZA in obtaining and maintaining remission of lupus nephritis (LN) is comparable over the long term. https://medicalxpress.com/news/2019-06-cyclosporine-benefits-patients-rapid-remission.html Arthritis & Rheumatism Wed, 12 Jun 2019 03:11:25 EDT news479527879 The results of the low-dose prednisolone in patients with hand osteoarthritis (HOPE) study presented today at the Annual European Congress of Rheumatology (EULAR 2019) show that low-dose prednisolone significantly improves pain and function in patients with painful hand osteoarthritis. https://medicalxpress.com/news/2019-06-low-dose-prednisolone-significantly-pain-symptoms.html Arthritis & Rheumatism Wed, 12 Jun 2019 03:11:02 EDT news479527855 The results of a randomised controlled trial presented today at the Annual European Congress of Rheumatology (EULAR 2019) demonstrate high levels of treatment success in approximately two thirds of patients despite tapered glucocorticoid (GC) discontinuation, while a small loss of disease control was observed at the total study population level. https://medicalxpress.com/news/2019-06-glucocorticoid-tapering-patients-disease-tocilizumab.html Arthritis & Rheumatism Wed, 12 Jun 2019 03:10:38 EDT news479527807 The results of a 14 country pan-European survey presented today at the Annual European Congress of Rheumatology (EULAR 2019) suggest gout is being diagnosed late, is not well controlled, and is not regularly monitored. https://medicalxpress.com/news/2019-06-gout-patients-silence-treatment.html Arthritis & Rheumatism Wed, 12 Jun 2019 03:10:00 EDT news479527788 The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2019) demonstrate that occupational exposure to inorganic dust is a previously unknown risk factor for gout and also confirm known risk factors, such as alcoholism and obesity. https://medicalxpress.com/news/2019-06-exposure-inorganic-gout-women.html Arthritis & Rheumatism Wed, 12 Jun 2019 03:09:35 EDT news479527769 The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2019) demonstrate that remission in patients with rheumatoid arthritis is associated with an 80% reduction in risk of cardiovascular outcomes. https://medicalxpress.com/news/2019-06-disease-remission-reduction-cardiovascular-outcomes.html Arthritis & Rheumatism Wed, 12 Jun 2019 03:09:00 EDT news479527732 The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2019) demonstrate significant correlation between body mass index (BMI) and disease severity in psoriatic arthritis. https://medicalxpress.com/news/2019-06-overweight-linked-significantly-higher-disease.html Arthritis & Rheumatism Wed, 12 Jun 2019 03:08:22 EDT news479527692 The results of a 23-year, follow-up study presented today at the Annual European Congress of Rheumatology (EULAR 2018) suggest early, intensive treatment of rheumatoid arthritis has long-term benefits including the normalisation of mortality to levels consistent with the general population. https://medicalxpress.com/news/2018-06-early-intensive-treatment-ra-long-term.html Arthritis & Rheumatism Fri, 15 Jun 2018 13:43:31 EDT news448289002 The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2018) demonstrate that canakinumab significantly reduced the rate of gout by more than half compared to placebo, regardless of baseline serum urate level. https://medicalxpress.com/news/2018-06-canakinumab-shown-gout-atherosclerosis.html Arthritis & Rheumatism Fri, 15 Jun 2018 12:48:52 EDT news448285710 The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2018) show that a one-yearly infusion of zoledronic acid (ZA) did not significantly reduce knee pain or bone marrow lesion (BML) size overall in knee osteoarthritis patients over two years. However, it may have symptomatic benefit in milder disease. https://medicalxpress.com/news/2018-06-zoledronic-acid-effect-knee-pain.html Arthritis & Rheumatism Fri, 15 Jun 2018 12:38:50 EDT news448285120 The results of an open label extension of a phase II study presented today at the Annual European Congress of Rheumatology (EULAR 2018) demonstrate that lenabasum continues to have acceptable safety and tolerability in diffuse cutaneous systemic sclerosis (dcSSc) with no severe or serious adverse events (AE). https://medicalxpress.com/news/2018-06-treatment-lenebasum-diffuse-cutaneous-sclerosis.html Arthritis & Rheumatism Fri, 15 Jun 2018 12:20:16 EDT news448284006